Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review

Rong Wang, Yingying Zhang, Xia Lin, Yalin Gao and Ying Zhu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:57327-57336. https://doi.org/10.18632/oncotarget.16905

Metrics: PDF 2429 views  |   HTML 3275 views  |   ?  


Rong Wang1,*, Yingying Zhang2,*, Xia Lin1, Yalin Gao2 and Ying Zhu1

1Department of Gynecology, Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China

2Department of Breast Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

*These authors contributed equally to this work

Correspondence to:

Ying Zhu, email: [email protected]

Keywords: CD73-adenosinergic pathway, overall survival, disease-free survival, solid tumor

Received: February 01, 2017     Accepted: March 24, 2017     Published: April 06, 2017


CD73 is a glycosylphosphatidylinositol (GPI) anchored cell surface protein that is encoded by NT5E gene, plays multiple roles in tumor processes. Previous studies have presented a potential value of CD73 served as a detectable biomarker for prognosis of several solid tumors, but the results were more controversially. A comprehensive meta-analysis was conducted to precisely evaluate the prognostic role of CD73 in solid tumors. The included studies were searched in PubMed, Web of Science and EBSCO from Jan 1990 to Jan 2016. Pooled hazard ratios (HR) and corresponding 95% confidence intervals (CI) for overall survival (OS), disease free survival (DFS) were carried out using a fixed or random effects model. Totally, 13 studies about 12,533 patients were included. CD73-high expression was correlating with poor OS (pooled HR = 1.28, 95% CI = 1.19–1.37). In addition, CD73 expression had borderline association with worse DFS (pooled HR = 1.28, 95% CI = 1.01–1.62). Egger’s tests indicated that there was no evidence of significant publication bias. CD73 is an efficient prognostic biomarker in solid tumors, and over-expression of CD73 is associated with inverse OS or DFS. But this predictive value and target therapy for clinical practice yet needs advanced research.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16905